Compare Cadila Healthcare with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs CIPLA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE CIPLA CADILA HEALTHCARE/
CIPLA
 
P/E (TTM) x 25.1 29.3 85.8% View Chart
P/BV x 4.4 4.1 106.5% View Chart
Dividend Yield % 0.8 0.5 158.6%  

Financials

 CADILA HEALTHCARE   CIPLA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
CIPLA
Mar-20
CADILA HEALTHCARE/
CIPLA
5-Yr Chart
Click to enlarge
High Rs352586 60.2%   
Low Rs207357 57.9%   
Sales per share (Unadj.) Rs139.2207.0 67.2%  
Earnings per share (Unadj.) Rs11.818.6 63.3%  
Cash flow per share (Unadj.) Rs18.633.2 56.0%  
Dividends per share (Unadj.) Rs3.504.00 87.5%  
Dividend yield (eoy) %1.30.8 147.6%  
Book value per share (Unadj.) Rs101.4195.5 51.8%  
Shares outstanding (eoy) m1,023.74806.35 127.0%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x2.02.3 88.2%   
Avg P/E ratio x23.725.3 93.7%  
P/CF ratio (eoy) x15.014.2 105.9%  
Price / Book Value ratio x2.82.4 114.4%  
Dividend payout %29.821.5 138.3%   
Avg Mkt Cap Rs m286,033379,912 75.3%   
No. of employees `00013.425.8 51.9%   
Total wages/salary Rs m24,14530,270 79.8%   
Avg. sales/employee Rs Th10,632.76,459.6 164.6%   
Avg. wages/employee Rs Th1,801.21,171.2 153.8%   
Avg. net profit/employee Rs Th898.5580.2 154.9%   
INCOME DATA
Net Sales Rs m142,531166,949 85.4%  
Other income Rs m1,1393,442 33.1%   
Total revenues Rs m143,670170,391 84.3%   
Gross profit Rs m24,19832,060 75.5%  
Depreciation Rs m6,96511,747 59.3%   
Interest Rs m3,4181,974 173.2%   
Profit before tax Rs m14,95421,782 68.7%   
Minority Interest Rs m288-475 -60.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1986,312 50.7%   
Profit after tax Rs m12,04414,995 80.3%  
Gross profit margin %17.019.2 88.4%  
Effective tax rate %21.429.0 73.8%   
Net profit margin %8.59.0 94.1%  
BALANCE SHEET DATA
Current assets Rs m87,154117,038 74.5%   
Current liabilities Rs m82,69443,931 188.2%   
Net working cap to sales %3.143.8 7.1%  
Current ratio x1.12.7 39.6%  
Inventory Days Days7196 74.6%  
Debtors Days Days9485 110.3%  
Net fixed assets Rs m133,236107,424 124.0%   
Share capital Rs m1,0241,613 63.5%   
"Free" reserves Rs m102,733156,018 65.8%   
Net worth Rs m103,757157,630 65.8%   
Long term debt Rs m32,14623,693 135.7%   
Total assets Rs m236,866236,626 100.1%  
Interest coverage x5.412.0 44.7%   
Debt to equity ratio x0.30.2 206.1%  
Sales to assets ratio x0.60.7 85.3%   
Return on assets %6.57.2 91.0%  
Return on equity %11.69.5 122.0%  
Return on capital %13.712.8 106.9%  
Exports to sales %033.0 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,175 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,75256,036 94.1%   
Fx outflow Rs m14,5046,764 214.4%   
Net fx Rs m38,24849,272 77.6%   
CASH FLOW
From Operations Rs m25,05430,685 81.7%  
From Investments Rs m-10,1231,040 -973.0%  
From Financial Activity Rs m-10,942-29,488 37.1%  
Net Cashflow Rs m3,9892,340 170.5%  

Share Holding

Indian Promoters % 74.8 16.0 467.5%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 8.3 12.2 68.0%  
FIIs % 5.9 23.7 24.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 11.0 26.2 42.0%  
Shareholders   44,069 161,166 27.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ALEMBIC  AUROBINDO PHARMA  IPCA LABS  FDC  SUN PHARMA  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat, GAIL and UPL Among Top Nifty Gainers(Closing)

Indian share markets continued their volatile trend during closing hours today and ended their day on a flat note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Mar 8, 2021 03:32 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - PANACEA BIOTECH COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS